MA27483A1 - Derives d'azole-pyrimidines fondues - Google Patents

Derives d'azole-pyrimidines fondues

Info

Publication number
MA27483A1
MA27483A1 MA28247A MA28247A MA27483A1 MA 27483 A1 MA27483 A1 MA 27483A1 MA 28247 A MA28247 A MA 28247A MA 28247 A MA28247 A MA 28247A MA 27483 A1 MA27483 A1 MA 27483A1
Authority
MA
Morocco
Prior art keywords
azole
pathologies
disease
pyrimidine derivatives
present
Prior art date
Application number
MA28247A
Other languages
English (en)
Inventor
Mitsuyuki Shimada
Toshiki Murata
Kinji Fuchikami
Hideki Tsujishita
Naoki Omori
Issei Kato
Mami Miura
Klaus Urbahns
Florian Gantner
Kevin Bacon
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of MA27483A1 publication Critical patent/MA27483A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne de nouveaux dérivés d'azole-pyrimidines fondues, des procédés permettant de les préparer et des préparations pharmaceutiques les contenant. Les dérivés d'azole-pyrimidines fondues de la présente invention présentent une capacité renforcée d'inhibition de la phosphotidylinositol-3-kinase (P13K), notamment d'inhibition de la P13K-(gamma) et peuvent s'utiliser pour assurer la prophylaxie et le traitement de pathologies associées à la P13K et en particulier à l'activité de la P13K-(gamma). Les dérivés d'azole de la présente invention s'utilisent plus particulièrement dans le traitement et la prophylaxie des pathologies suivantes : troubles inflammatoires et immunorégulateurs. tels que l'asthme, la dermatite atopique, la rhinite, les maladies allergiques, la maladie pulmonaire obstructive chronique (COPD), le choc septique, les maladies des articulations, les pathologies auto-immunes telles que la polyarthrite rhumatoïde, et la maladie de Graves, le cancer, les troubles de contractilité du myocarde, l'insuffisance cardiaque, le thromboembolisme, l'ischémie et l'athérosclérose. Les composés de la présente invention s'utilisent également pour traiter l'hypertension pulmonaire, l'insuffisance rénale, l'hypertrophie cardiaque, de même que des troubles neurodégénératifs tels que la maladie de Parkinson, la maladie d'Alzheimer, le diabète et l'ischémie focale, ces pathologies se rapportant également à l'activité de la P13K, chez l'homme ou l'animal.
MA28247A 2002-09-30 2005-04-29 Derives d'azole-pyrimidines fondues MA27483A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02021861 2002-09-30

Publications (1)

Publication Number Publication Date
MA27483A1 true MA27483A1 (fr) 2005-08-01

Family

ID=32039115

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28247A MA27483A1 (fr) 2002-09-30 2005-04-29 Derives d'azole-pyrimidines fondues

Country Status (33)

Country Link
US (2) US7511041B2 (fr)
EP (2) EP1549652B1 (fr)
JP (1) JP4790266B2 (fr)
KR (1) KR101059652B1 (fr)
CN (1) CN100384846C (fr)
AR (2) AR041426A1 (fr)
AT (2) ATE411996T1 (fr)
AU (1) AU2003293310B2 (fr)
BR (1) BRPI0314830B8 (fr)
CA (1) CA2499134C (fr)
CY (2) CY1109790T1 (fr)
DE (1) DE60324296D1 (fr)
DK (2) DK1549652T3 (fr)
EC (2) ECSP055768A (fr)
ES (2) ES2367141T3 (fr)
HK (1) HK1084393A1 (fr)
HR (2) HRP20050375B1 (fr)
IL (1) IL166855A (fr)
MA (1) MA27483A1 (fr)
MX (1) MXPA05001808A (fr)
MY (1) MY140756A (fr)
NO (1) NO331457B1 (fr)
NZ (1) NZ539062A (fr)
PE (1) PE20050089A1 (fr)
PL (1) PL226562B1 (fr)
PT (2) PT1549652E (fr)
RU (1) RU2326881C9 (fr)
SI (2) SI1549652T1 (fr)
TW (1) TWI327570B (fr)
UA (1) UA82205C2 (fr)
UY (1) UY28001A1 (fr)
WO (1) WO2004029055A1 (fr)
ZA (1) ZA200503306B (fr)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
CA2537124C (fr) 2003-08-29 2012-08-07 Mitsui Chemicals, Inc. Insecticide s'utilisant en agriculture ou en horticulture et procede d'utilisation correspondant
US7932260B2 (en) 2004-05-13 2011-04-26 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
CA2579279C (fr) 2004-10-07 2013-10-01 Boehringer Ingelheim International Gmbh Derives de thiazole tricyclique en tant que pi3-kinases
WO2006040645A1 (fr) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited Derives de benzamide n-(3,5-dichloropyridine-4-yle)-2,4,5-alcoxy et 2,3,4 alcoxy en tant qu'inhibiteurs de pde-iv (phosphodiesterase de type iv) pour traiter des maladies inflammatoires telles que l'asthme
EP3770278A1 (fr) 2005-04-14 2021-01-27 The Trustees of Boston University Diagnostic des troubles pulmonaires à l'aide d'une prédiction de classe
UA97348C2 (en) * 2005-07-29 2012-02-10 4Сц Аг HETEROCYCLIC NF-kB INHIBITORS
CA2645310A1 (fr) 2006-03-09 2007-09-13 The Trustees Of Boston University Methodes de diagnostic et de pronostic pour troubles des poumons utilisant des profils d'expression de genes de cellules epitheliales nasales
US7691868B2 (en) 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
US7517995B2 (en) * 2006-04-06 2009-04-14 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-cyclopentapyrazole
ATE532788T1 (de) * 2006-04-26 2011-11-15 Hoffmann La Roche Pharmazeutische verbindungen
WO2008064244A2 (fr) * 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Modulation des phosphoinositides pour le traitement de maladies neurodégénératives
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP1953163A1 (fr) * 2007-02-01 2008-08-06 Boehringer Ingelheim Pharma GmbH & Co. KG Dérivés de Pteridinone comme inhibiteurs des Kinases PI3
WO2008148023A2 (fr) * 2007-05-23 2008-12-04 Medical College Of Georgia Research Institute, Inc. Compositions et procédés pour traiter des troubles neurologiques
WO2009039140A1 (fr) * 2007-09-17 2009-03-26 Smithkline Beecham Corporation Dérivés de pyridopyrimidine en tant qu'inhibiteurs de kinase p13
EP2193211A4 (fr) * 2007-09-19 2010-12-08 Univ Boston Identification de nouvelles voies pour le développement de médicaments destinés à traiter une maladie des poumons
JP5620275B2 (ja) * 2008-01-14 2014-11-05 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 超増殖性疾患及び脈管形成に関連する疾病を処理するために有用なスルホン置換された２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン誘導体類
JP5581219B2 (ja) 2008-01-25 2014-08-27 ミレニアム ファーマシューティカルズ， インコーポレイテッド チオフェンおよびホスファチジルイノシトール３−キナーゼ（ｐｉ３ｋ）阻害薬としてのその使用
WO2009111547A1 (fr) * 2008-03-04 2009-09-11 Wyeth Composés de 7h-pyrrolo[2,3-h]quinazoline, leur utilisation comme inhibiteurs de la mtor kinase et de la pi3-kinase, et leur synthèse
WO2009128520A1 (fr) * 2008-04-18 2009-10-22 塩野義製薬株式会社 Composé hétérocyclique présentant une activité inhibitrice sur p13k
EP2303890A4 (fr) * 2008-06-19 2012-04-11 Progenics Pharm Inc Inhibiteurs de phosphatidylinositol 3 kinase
EP2168582A1 (fr) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Combinaisons de 2,3-dihydroimidazo[1,2-c]quinazolines substituées
EP2168583A1 (fr) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées pour le traitement du myélome
ES2614130T3 (es) * 2008-09-30 2017-05-29 Pfizer Inc. Compuestos de imidazo[1,5]naftiridina, su uso farmacéutico y composiciones
BRPI0915273B1 (pt) * 2008-11-11 2021-08-03 Je Il Pharmaceutical Co., Ltd Derivado tricíclico ou seus sais farmaceuticamente aceitáveis e seus métodos de preparação
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
ES2674719T3 (es) 2008-11-13 2018-07-03 Gilead Calistoga Llc Terapias para neoplasias hematológicas
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
CA2750935A1 (fr) 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryles et applications associees
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
EP2411391A1 (fr) 2009-03-24 2012-02-01 Gilead Calistoga LLC Atropisomères de dérivés de 2-purinyl-3-tolyl-quinazolinone et procédés d'utilisation
CN102458410A (zh) 2009-04-20 2012-05-16 吉联亚·卡利斯托加有限责任公司 治疗实体瘤的方法
SI2899191T1 (sl) * 2009-04-30 2017-11-30 Glaxo Group Limited Z oksazolom substituirani indazoli kot PI3-kinazni inhibitorji
CN102647987A (zh) 2009-07-21 2012-08-22 吉里德卡利斯托加公司 使用pi3k抑制剂治疗肝脏障碍
NZ626650A (en) * 2009-09-09 2015-12-24 Celgene Avilomics Res Inc Pi3 kinase inhibitors and uses thereof
MX2012012064A (es) * 2010-04-16 2012-12-17 Bayer Ip Gmbh Combinaciones que contienen 2,3-dihidroimidazo[1,2-c]quinazolina sustituida.
WO2012021611A1 (fr) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Hétéroaryles et utilisations de ceux-ci
US9381177B2 (en) 2010-10-01 2016-07-05 Bayer Intellectual Property Gmbh Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
CN103370320B (zh) * 2010-11-11 2016-04-27 拜耳知识产权有限责任公司 芳基氨基醇取代的2,3-二氢咪唑并[1,2-c]喹啉
ES2646012T3 (es) 2010-11-11 2017-12-11 Bayer Intellectual Property Gmbh 2,3-Dihidroimidazo[1,2-c]quinazolinas sustituidas con alcoxi
UA113280C2 (xx) * 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (fr) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Sels de 2,3-dihydroimidazo[1,2-C]quinazoline substitutés
AR090253A1 (es) 2012-03-05 2014-10-29 Gilead Calistoga Llc Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluor-3-fenilquinazolin-4(3h)-ona
EP2968988A4 (fr) 2013-03-14 2016-11-16 Allegro Diagnostics Corp Procédés d'évaluation de l'état d'une maladie pulmonaire obstructive chronique (copd)
US20160143910A1 (en) 2013-03-15 2016-05-26 Constellation Pharmaceuticals, Inc. Methods of treating cancer and preventing cancer drug resistance
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
PE20151780A1 (es) 2013-04-08 2015-12-20 Bayer Pharma AG Uso de 2 - 3 dihidroimidazo[ 1,2- c] quinazolinas sustituidas
WO2014177060A1 (fr) 2013-05-01 2014-11-06 F.Hoffmann-La Roche Ag Composés bihétéroaryle et leurs utilisations
WO2015027431A1 (fr) * 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. Antagonistes 2,2-difluorodioxolo du récepteur a2a
US9708327B2 (en) 2013-12-20 2017-07-18 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
MX2016008259A (es) 2013-12-20 2016-10-13 Gilead Calistoga Llc Metodo de proceso para inhibidores de fosfatidilinositol 3-cinasa.
SG11201609877XA (en) 2014-06-13 2016-12-29 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
EP3770274A1 (fr) 2014-11-05 2021-01-27 Veracyte, Inc. Systèmes et procédés de diagnostic de la fibrose pulmonaire idiopathique sur des biopsies transbronchiques à l'aide de l'apprentissage automatique et de données de transcription dimensionnelle élevée
EP3018127A1 (fr) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthèse de copanlisib et son sel de dichlorhydrate
EP3018131A1 (fr) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthèse de copanlisib et son sel de dichlorhydrate
SG11201707240SA (en) 2015-03-09 2017-10-30 Bayer Pharma AG Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
CN105130997B (zh) * 2015-09-25 2017-12-05 苏州明锐医药科技有限公司 一种库潘尼西的制备方法
CN105130998B (zh) * 2015-09-25 2017-07-28 苏州立新制药有限公司 库潘尼西的制备方法
WO2017153220A1 (fr) 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2-amino-n-[7-méthoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides
EP3219329A1 (fr) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinaisons de copanlisib
US10927417B2 (en) 2016-07-08 2021-02-23 Trustees Of Boston University Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions
JP2019532922A (ja) 2016-09-23 2019-11-14 バイエル ファーマ アクチエンゲゼルシャフト Ｐｉ３ｋ−阻害剤の組み合わせ
WO2018112176A1 (fr) 2016-12-14 2018-06-21 Tarveda Therapeutics, Inc. Conjugués ciblant hsp90 et formulations de ces derniers
EP3585437B1 (fr) 2017-02-24 2022-12-21 Bayer Pharma Aktiengesellschaft Combinaisons de copanlisib avec un anticorps anti-pd-1
CA3068324A1 (fr) 2017-06-28 2019-01-03 Bayer Consumer Care Ag Combinaison d'un inhibiteur de pi3k et d'un antagoniste du recepteur des androgenes
HUE063178T2 (hu) 2017-09-08 2023-12-28 Bayer Pharma AG Kopanlizib formulációi
EP3498266A1 (fr) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations de copanlisib
JP7394768B2 (ja) * 2017-09-20 2023-12-08 エイビーエム セラピューティックス コーポレイション キナーゼ阻害剤としての環状イミノピリミジン誘導体
US11351156B2 (en) 2017-10-13 2022-06-07 Inserm Combination treatment of pancreatic cancer
WO2019101871A1 (fr) 2017-11-23 2019-05-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) Nouveau marqueur permettant de prédire la sensibilité à des inhibiteurs de pi3k
WO2019105734A1 (fr) 2017-11-28 2019-06-06 Bayer Consumer Care Ag Combinaisons de copanlisib
WO2019105835A1 (fr) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinaisons de copanlisib et d'anetumab ravtansine
WO2019197269A1 (fr) 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinaisons de copanlisib et de dérivés de triazolone ainsi que leur utilisation dans le traitement du cancer
WO2020020385A1 (fr) * 2018-07-27 2020-01-30 上海翰森生物医药科技有限公司 Inhibiteur de dérivé tricyclique, son procédé de préparation et application
CN109053554B (zh) * 2018-08-01 2020-07-28 江苏八巨药业有限公司 一种使用催化剂合成3-乙酰吡啶的方法
EP3843743A1 (fr) 2018-08-28 2021-07-07 Bayer AS Combinaison d'inhibiteurs de pi3k et de conjugués de thorium ciblés
WO2020078788A1 (fr) 2018-10-16 2020-04-23 Bayer Aktiengesellschaft Combinaison d'inhibiteurs de kinase atr avec des composés de 2,3-dihydro-imidazo[1,2-c]quinazoline
CA3118493A1 (fr) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion de til utilisant des inhibiteurs de la voie akt
EP3903828A4 (fr) 2018-12-21 2022-10-05 Daiichi Sankyo Company, Limited Combinaison d'un conjugué anticorps-médicament et d'un inhibiteur de kinase
WO2020164997A1 (fr) 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combinaison d'inhibiteurs de la pi3k
CN114621236B (zh) * 2022-04-25 2024-06-18 河南湾流生物科技有限公司 一种喹啉类饲料添加剂的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644354A (en) * 1968-09-16 1972-02-22 Sandoz Ag 5-substituted-2 3-dihydroimidazo(1 2-c)quinazolines
US4287341A (en) 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
CN1033644C (zh) * 1993-01-02 1996-12-25 瑞安大药厂股份有限公司 3-取代甲基-2，3-二氢咪唑并[1，2-c]喹唑啉衍生物，其制备与用途
WO1996004923A1 (fr) 1994-08-12 1996-02-22 Pro-Neuron, Inc. Procedes permettant de traiter la sepsie ou des maladies inflammatoires avec des nucleosides a base d'oxypurine
WO1997027177A2 (fr) * 1996-01-29 1997-07-31 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Derives de dihydropyridine-, pyridine-, benzopyrane- mono- et triazoloquinazoline, leur preparation, et utilsation comme antagonistes des recepteurs de l'adenosine
US5932584A (en) * 1997-05-06 1999-08-03 National Science Council Optically active 2,3-dihydroimidazo(1,2-C) quinazoline derivatives, the preparation and antihypertensive use thereof
ATE502941T1 (de) 2000-04-25 2011-04-15 Icos Corp Hemmer der menschlichen phosphatidyl-inositol-3- kinase delta
DE60144322D1 (de) * 2000-04-27 2011-05-12 Astellas Pharma Inc Kondensierte heteroarylderivate

Also Published As

Publication number Publication date
NO331457B1 (no) 2012-01-09
PE20050089A1 (es) 2005-04-20
KR101059652B1 (ko) 2011-08-25
KR20050067404A (ko) 2005-07-01
ECSP11005768A (es) 2011-03-31
IL166855A (en) 2014-05-28
DK2042504T3 (da) 2011-09-19
ES2367141T3 (es) 2011-10-28
JP4790266B2 (ja) 2011-10-12
SI2042504T1 (sl) 2011-10-28
US20060128732A1 (en) 2006-06-15
TWI327570B (en) 2010-07-21
DE60324296D1 (de) 2008-12-04
UY28001A1 (es) 2004-04-30
TW200413379A (en) 2004-08-01
PT1549652E (pt) 2008-12-15
ES2312843T3 (es) 2009-03-01
CA2499134C (fr) 2011-12-20
DK1549652T3 (da) 2009-02-23
HK1084393A1 (en) 2006-07-28
PL375935A1 (en) 2005-12-12
AR072458A2 (es) 2010-09-01
BR0314830A (pt) 2005-08-16
RU2005113165A (ru) 2005-10-10
EP1549652B1 (fr) 2008-10-22
UA82205C2 (en) 2008-03-25
NO20052076L (no) 2005-04-27
AR041426A1 (es) 2005-05-18
RU2326881C9 (ru) 2009-04-10
WO2004029055A1 (fr) 2004-04-08
BRPI0314830B8 (pt) 2021-05-25
EP2042504A1 (fr) 2009-04-01
HRP20131159A2 (hr) 2014-05-23
ZA200503306B (en) 2006-07-26
CN1688582A (zh) 2005-10-26
PL226562B1 (pl) 2017-08-31
JP2006508063A (ja) 2006-03-09
US20090270388A1 (en) 2009-10-29
CY1112174T1 (el) 2015-12-09
AU2003293310A1 (en) 2004-04-19
CN100384846C (zh) 2008-04-30
RU2326881C2 (ru) 2008-06-20
US8129386B2 (en) 2012-03-06
MXPA05001808A (es) 2005-08-16
PT2042504E (pt) 2011-09-07
EP2042504B1 (fr) 2011-06-01
CY1109790T1 (el) 2014-09-10
EP1549652A1 (fr) 2005-07-06
ATE511510T1 (de) 2011-06-15
SI1549652T1 (sl) 2009-04-30
ATE411996T1 (de) 2008-11-15
US7511041B2 (en) 2009-03-31
BRPI0314830B1 (pt) 2018-03-27
AU2003293310B2 (en) 2010-04-01
HRP20131159B1 (hr) 2019-11-01
HRP20050375A2 (en) 2006-05-31
ECSP055768A (es) 2005-08-11
NZ539062A (en) 2007-05-31
MY140756A (en) 2010-01-15
CA2499134A1 (fr) 2004-04-08
HRP20050375B1 (hr) 2014-03-14

Similar Documents

Publication Publication Date Title
MA27483A1 (fr) Derives d'azole-pyrimidines fondues
Neueder et al. The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington’s disease patients
MXPA04004019A (es) Derivados de pirimido?4,5-b?indol.
MA30318B1 (fr) Composes de sulfonamide de pyrimidinyle inhibant l'adhesion leucocytaire mediee par vla-4
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
ATE187447T1 (de) 3-phenyl-2-isoxazoline derivate als entzündugshemmende mittel
TNSN04111A1 (fr) Derives de quinazoline pour le traitement d'une croissance cellulaire anormale
Nandakishore et al. Selective cyclooxygenase inhibitors: current status
MA27491A1 (fr) Derives de phenyl-ou heteroarylamino-alcanes comme antagonistes ou recepteur ip
MA24694A1 (fr) Derives de thienopyrimidine et thienopyridine utiles comme agents anticancereux, et compositions les contenant.
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
ES2104424T3 (es) Compuestos de isoxazolina como agentes antiinflamatorios.
MA33772B1 (fr) Dérivés d'acide carboxylique cyclique substitué par acylamino et leur utilisation en tant qu'agents pharmaceutiques
MA31862B1 (fr) Anticorps anti-mésothéline et leurs utilisations
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
WO2001012171A3 (fr) Composition et procede neurotherapeutiques a base de clavulanate
Cougnoux et al. Necroptosis inhibition as a therapy for Niemann-Pick disease, type C1: Inhibition of RIP kinases and combination therapy with 2-hydroxypropyl-β-cyclodextrin
MA31397B1 (fr) Sels de [4(-(6-fluoro-7-méthylamino-2, 4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phényl]-5-chloro-thiophén-2-yl-sulfonylurée, formes et procédés qui leur sont associés
MA35567B1 (fr) Nouvelle formulation de méloxicam
MA32798B1 (fr) Acides naphtylacétiques
TW200502221A (en) Novel lactams and uses thereof
EA200500172A1 (ru) Азабициклопроизводные в качестве антагонистов мускариновых рецепторов
JP2010248224A (ja) 治療又は予防薬
MA27690A1 (fr) Composition pharmaceutique androgene et procede pour le traitement de la depression.
MA44018B1 (fr) Dérivés de tétrahydroisoquinoline